A couple of somewhat promising phase 2 trial results

Status
Not open for further replies.

Buglaw

Active member
Joined
Jun 20, 2022
Messages
79
Reason
DX MND
Diagnosis
10/2022
Country
US
State
IL
City
Chicago
I just wanted to flag that there have been a couple of somewhat promising phase 2 trial results that came out this week for various subsets of ALS patients.



The NP-001 is particularly interesting as it showed a significant slowdown in disease progression for individuals with mildly elevated c-reactive protein, including 40% of participants who more or less did not progress for the 6 month study.
 
I'm interested in what the company behind NP001 is going to do next - they haven't announced that they are yet going to run a phase 3 trial. They did put out a press release earlier this year that they were getting manufacturing ready.

"The company expects to have product available by the end of the year for clinical use."


I am curious to see whether they are going to try to submit to the FDA based on their phase 2 data, similar to what Amylyx did.
 
Based on this article, Neuvivo is indeed aiming at that pathway (conditional approval pending Phase 3).
 
Status
Not open for further replies.
Back
Top